WO1986006487A1 - Methode de determination de mimotopes - Google Patents
Methode de determination de mimotopes Download PDFInfo
- Publication number
- WO1986006487A1 WO1986006487A1 PCT/AU1986/000110 AU8600110W WO8606487A1 WO 1986006487 A1 WO1986006487 A1 WO 1986006487A1 AU 8600110 W AU8600110 W AU 8600110W WO 8606487 A1 WO8606487 A1 WO 8606487A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monomers
- catamers
- catamer
- receptor
- solid support
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 239000000178 monomer Substances 0.000 claims abstract description 123
- 239000003446 ligand Substances 0.000 claims abstract description 35
- 125000006850 spacer group Chemical group 0.000 claims abstract description 15
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 11
- 230000000295 complement effect Effects 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims description 29
- 230000003287 optical effect Effects 0.000 claims description 7
- 230000009897 systematic effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 108020003175 receptors Proteins 0.000 description 48
- 102000005962 receptors Human genes 0.000 description 48
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 16
- 241000700605 Viruses Species 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229940000635 beta-alanine Drugs 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 150000001371 alpha-amino acids Chemical class 0.000 description 6
- 235000008206 alpha-amino acids Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102100030856 Myoglobin Human genes 0.000 description 5
- 108010062374 Myoglobin Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000283222 Physeter catodon Species 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 241001415846 Procellariidae Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- -1 beta-amino acids Chemical class 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- DWCSTCCKNZMDHA-UHFFFAOYSA-N 3-(3-aminopropanoylamino)propanoic acid Chemical compound NCCC(=O)NCCC(O)=O DWCSTCCKNZMDHA-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- 229930182847 D-glutamic acid Natural products 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- TVMBQERGBYQPAM-UHFFFAOYSA-N 3-amino-n-(6-aminohexyl)propanamide Chemical compound NCCCCCCNC(=O)CCN TVMBQERGBYQPAM-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical class C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000740 envenomation Toxicity 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Definitions
- This invention relates to a method of detecting or determining a sequence of monomer molecules which corresponds to the ligand molecule for a particular receptor.
- the sequence of monomer molecules so determined is the mimotope (defined below) of the particular ligand.
- the mimotope which is determined by this method may not have any obvious or direct relationship to the natural ligand molecule, but will share with it the ability ' to react with the receptor, and indeed, the mimotope so determined may be modified to incorporate specific or additional properties in the reaction with the receptor.
- Such a mimotope could then be used to replace the natural ligand in the treatment or prevention of particular disease or it may be used to mediate a particular biological effect.
- receptor a molecule or molecular complex which will combine specifically with its particular ligand molecule. It is those receptors which on binding with their particular ligand(s) mediate a biological function that are of most interest.
- Examples of receptors include, but are not restricted to, the common class of receptors associated with the surface membrane of cells and include, for instance, the immunologically important receptors of B-cells, T-cells, macrophages and the like.
- Another example is receptors for acetyl choline on nerve cells which cause a nerve pulse to be transmitted down the length of the neuron when the receptor molecule reacts with its ligand, acetyl choline.
- epitope the specific surface of an antigen molecule which is delineated by the area of interaction with the sub-class of receptors known as antibodies.
- catamer a polymer molecule which is a precisely defined linear sequence formed by the condensation of small molecules. Note that this term includes molecules in which different types of condensation reactions are used to join the small molecules. A number prefixed to the word "catamer” implies that the catamer is formed by the condensation of the indicated number of small molecules, for example, 8-catamer means that the catamer is made up from eight small molecules. Examples of catamers include any given peptide and any given oligo-saccharide.
- the monomer a member of the set of small molecules which can be condensed together to form a catamer.
- the set of monomers includes but is not restricted to, for example, the set of common L-amino acids, the set of D-amino acids, the set of synthetic amino acids, the set of nucleotides, and the set of pentoses and hexoses.
- peptide a catamer in which the small molecules are alpha-amino acids and which are joined together through a peptide bond.
- amino acids may be the L-optical.isomer or the D-optical isomer.
- mimotope a catamer which in at least one of its conformations has a surface region with the equivalent molecular topology to the binding surface of the ligand molecule of which it is the mimic. In the context of immunological ⁇ receptors, the mimotope mimics the. epitope of the antigen.
- complementary refers to the matching together of the reacting surfaces of an ligand molecule and its receptor.
- the receptor and its ligand can be described as complementary, and furthermore, the contact surface characteristics are complementary to each other.
- paratope the combining site of an antibody which is complementary to a particular epitope.
- ligand molecule is the molecule which binds to a particular receptor and when bound to it mediates the biological function associated with that particular receptor.
- receptors which can be investigated by this method include, but are not restricted to:
- hormone receptors for instance the receptors for insulin and Growth Hormone; determination of the mimotopes of the ligands binding to these receptors may lead to the development of an oral replacement of the daily injections which diabetics must take to relieve the symptoms of diabetes, and in the other case, a replacement for the scarce human Growth Hormone which can only be obtained from cadavers or by recombinant DNA technology.
- Other examples are the vasoconstrictive hormone receptors; determination of the mimotope of the ligand binding to these receptors may lead to the ' development of drugs to control blood pressure.
- opiate receptors determination of mimotopes of the ligands binding to the opiate-receptors in the brain may lead to the development of less-addictive replacements for morphine and related drugs.
- microorganism receptors determination of mimotopes of the ligands binding to a receptor such as specific transport proteins or enzymes essential to survival to microorganisms, may lead to a new class of antibiotics. Of particular value would be antibiotics against protozoa and those bacteria resistant to the antibiotics in current use.
- enzymes for instance, the enzymes responsible for cleaving neural transmitters; determination of mimotopes able to modulate the action of the enzymes which cleave the different neural transmitters may lead to the development of drugs which can be used in the treatment of disorders of neural transmission; and,
- antibodies for instance the ligand-binding site on the antibody molecule which combines with the epitope of an antigen of interest; determination of a. mimotope for the epitope may lead to the development of vaccines of which the immunogen is based on one or more mimotopes or diagnostic agents or compounds useful in the therapeutic treatment of autoimmune diseases.
- ligands which can be investigated by this method include, but are not restricted to:
- toxins and venoms for instance, the combining site of the toxin molecule which reacts with a particular receptor in the body to give the particular symptom(s) of intoxication; determination of mimotopes to the combining site of the ligand may lead to the development of drugs which can be used to treat envenomation by snakes and other poisonous animals without the side effects of heterologous antivenenes.
- virus and other microorganism capsid molecules for instance, the combining site on the virus coat molecule which reacts with a particular receptor on the cell membrane in the body and which allows the virus to invade and thus infect the particular cell; determination of mimotopes to this combining site may lead to the development of drugs which specifically prevent intracellular invasion by the virus and thus prevent their replication.
- the most usual group* of small molecules which may be condensed together to form a catamer is the group of alpha-amino acids.
- other molecules which are consistent with a different chosen chemistry may also be used; for example, catamers formed from the specified sequential condensation of nucleotides or saccharides.
- Another group of small molecules would be the non-genetically coded amino acids such as beta-amino acids, which may be used to advantage to add an additional bond at specified positions within the catamer.
- the method of the present invention is based on the realisation that a given receptor will specifically react with a catamer which is the mimotope for the ligand to which the receptor is directed. It further relies on modern techniques of immunology to detect reaction between a receptor and its ligand when both are present.
- reaction is readily detected between a receptor and short mimotopes. These short mimotopes when condensed together then bind to the receptor with either a greater affinity or with greater specificity for that receptor. This reaction can be detected even when the short mimotope presented to the receptor is as small as two monomer molecules long.
- the final structure of a strongly-binding mimotope can be determined.
- a method of detecting or determining the sequence of monomers which is a topographical equivalent of the ligand which is complementary to the particular receptor of interest and prior knowledge is irrelevant about the identity, structure and sequence of the receptor or its ligand. The method comprises the steps of:-
- D 2- D l wherein D» represents a designated monomer selected from a first set of monomers, and D ⁇ represents a designated monomer selected from a second set of monomers which may be the same as or different to said first set of monomers; said plurality of catamers comprising catamers in which each designated monomer is systematically varied to contain members from the respective set of monomers;
- the method may also comprise the further steps of:
- D. and D 2 are as defined above, and preferably represent a combination of monomers corresponding to a catamer which binds to said receptor, and D, represents a designated monomer selected from a third set of monomers which may be the same as or different to either the first or the second set of monomers, and
- steps a. and b. above may be repeated to further "extend" the catamers by systematically adding further monomers to the catamers, and testing in the same manner as in step b, above.
- the metho ' d of this invention may comprise the steps of:
- D 2 -Sp- Dl wherein D, and D ? are as defined above and Sp is a spacer molecule which can modify the relative orientation of the monomers D 1 and D 2 ;
- the spacer molecule "Sp” as described above may also be systematically introduced into all possible positions of the "extended” catamers referred to above, and tested in the same manner as in Step B. above.
- the method of the invention may further comprise the steps of «. systematically replacing the monomers in any of the catamers referred to above with their optical isomers, either individually or in combinations of monomers, and again performing steps 2 and 3 as describe above.
- the method may further comprise the steps of systematically replacing the monomers in any of the catamers referred to above which bind with the receptor of interest, either individually or in combinations of monomers, with other monomers selected from the respective set(s) of monomers, and again performing steps 2 and 3 as described above.
- the method of this invention requires no previous information about the nature of the ligand and in particular it requires no foreknowledge of the sequence of monomers which make up the ligand. In fact, it is not necessary for the application of this invention to know the source or identity of the ligand to which the receptor is directed. Furthermore, this invention makes no assumptions about the nature of the ligand of the particular receptor. This method will identify mimotopes of discontinuous as well as continuous ligands. Because of the very nature of the method of the invention it will be appreciated that mimotopes may or may not consist of members of the same set of monomers which make up the ligand of which it is the mimic.
- the plurality of catamers required to be synthesized in the application of this invention may be prepared by any of the known method of catamer synthesis.
- the preferred methods when the monomers are amino acids is to use the solid phase technique described in Australian Patent Specification No. 25429/84, whereby each catamer is synthesized on a polyethylene support.
- the method of the present invention is carried out by screening a plurality of synthesized catamers against the antibody of interest.
- the antibody will be a monoclonal antibody which can be prepared by any of the usual methods. Polyclonal antiserum from humans and animals may be used if a source of monoclonal antibody with the desired characteristics is not available, however, analysis of the resulting data may be complicated because the reaction observed could be from more than one monoclonal antibody.
- polyclonal antiserum it may be necessary to reduce the antibody diversity by using techniques well known to those skilled in the art, for example iso-electric focusing, HPLC-based chromatography or affinity chromatography.
- Lk represents a linker molecule which provides a suitable end group for condensing the monomers to the solid support.
- D and “D.-” represent designated 0 positions occupied by monomers which are selected from known sets of monomers; but which are altered systematically between catamers. It should be noted that the set of monomers used for the D. designated position need not be the same set of monomers used for c the D 2 designated position.
- Y in the general formula is an end group of the catamer and may be, but is not restricted to, for example a hydrogen atom or an acetyl group. "Y” may also be another molecule which is coupled to the catamer to preserve particular Q characteristics of the molecular environment of a peptide bond at the amino terminal designated position.
- j . is the number of members in the set of monomers to be coupled in the D.. position and jj is the 5 number of members in the set of monomers to be coupled in the D ⁇ position then a total of ⁇ . j_ different catamers will be synthesized.
- the support rods are prepared so that the monomers can be coupled to them by coupling an appropriate linker molecule.
- each rod 0 will be treated with a reaction mixture which contains only a single monomer such as a protected amino acid or the like.
- each of the i. monomers are coupled to j. rods.
- each rod is treated with a reaction mixture which 5 contains a single monomer such as a protected amino acid or the like.
- Each of the j. rods which has a particular monomer in the D.. position will have a different monomer coupled at the D position. In this way every combination of the members of the set(s) of monomers Q - will be found in the i.. . rods.
- the desired end group, "Y” is then coupled using the appropriate chemistry.
- Sp is a spacer molecule which may restrict the relative orientation of the monomers at the designated positions to a particular geometrical configuration(s) .
- the spacer molecule may also be deliberately chosen to allow a greater flexibility to the relative geometric configuration between monomers in the designated positions, D.. and D . It should be noted that members of the set of spacer molecules may be made up from the condensation of more than one monomer.
- spacer molecules include, but are not restricted to g ⁇ ycine (approximately linear extension) , beta-alanine (increased flexibility) , proline (forced bend) , glycyl-proline (extended bend, otherwise known as reverse bend in protein structure terminology) and o-aminobenzoic acid (a planar bend) .
- the plurality of catamers prepared as in A. above are then contacted with the particular antibody of interest.
- the reaction between antibody and each catamer can then be detected by any of the usual methods, for example, radioimmunoassay (RIA) .
- RIA radioimmunoassay
- the preferred method of detection is to use the well known enzyme-linked im unosorbent assay (ELISA) .
- each assay antibodies can be removed from the catamers by, for example, washing with a solution of 8M urea, 0.1% 2-mercaptoethanol and 0.1% sodium dodecylsulphate followed by several washes in phosphate buffered saline. In this way the plurality of catamers may be used for testing with many other antibodies.
- the selected catamers can be synthesized using similar methods to those used in A. After the selected catamers have been synthesized they are reacted with the 10 antibody of interest. It is then simple to select the catamer which binds most strongly with the antibody.
- the binding of the mimotope with the antibody can be further enhanced by synthesizing a further
- This plurality of catamers consists of adding spacer molecules (-Sp-) systematically at all positions; of the mimotope; and where feasible systematically replacing each monomer of
- the mimotopes are being determined for the antigen against which different monoclonal antibodies were raised.
- the defined set of monomers is the set of the common L-alpha
- the linker molecule, -Lk- was 3 amino-N (6-aminohexyl)-propanamide and the end group, Y-, was the acetyl moiety.
- the mimotope is determined for an antigenic determinant of human chorionic gonadotrophin which
- the linker molecule, -Lk- is the same as that used in earlier Examples.
- the end group, Y- is either ⁇ -alanyl-3-alanine or ⁇ -alanine.
- the defined set of monomers was extended to include the D-optical isomers of the common alpha amino acids and several unusual amino acids. In Example 6 below, the mimotope is determined for a receptor site on viruses.
- the linker molecule, -Lk- is the same as for earlier Examples.
- the end group, Y- is either 0-alanyl- ⁇ -alanine or 8-alanine.
- the defined set of monomers was extended as described for Example 5.
- a monoclonal antibody was raised against sperm whale myoglobin using the usual techniques. This monoclonal antibody was tested against a set of catamers with the general formula:
- a further set of catamers was synthesized which comprised all 4-catamers which could be made from the set of monomers; Glutamic acid (E) , Phenylalanine (F) , Histidine (H) and Leucine (L) .
- the following catamers were found to bind significantly higher than the remaining catamers:-
- a monoclonal ⁇ ntibody was raised against sperm whale myoglobin using the usual techniques. This monoclonal antibody was tested against a set of catamers with the general formula:
- the structure below is a two dimensional representation of the spatial relationship between the amino acids, F, E, L, and H when bound to a monoclonal antibody against sperm whale myoglobin (see Example 2) . It must be noted * that this is an illustration only and must not be interpreted to mean that the catamer illustrated is planar. Furthermore, the bonds joining F to E and L to H are meant to represent a distance greater than that of a peptide bond.
- a mimotope to a monoclonal antiserum raised against Foot and Mouth Disease Virus was delineated to the sequence W-Q-M-G-H-S.
- a series of catamers were synthesized in which a beta-alanine residue was introduced systematically between monomers.
- the sequence W-Q-M- ⁇ -G-H-S gave a response which was significantly larger than the base sequence, where ⁇ represents beta-alanine. It was further found that excellent binding to the antibody was achieved with the sequences:
- the mimotope is made up of two parts; furthermore, the joining together of these parts is not critical for the mimotope to be able to react strongly with the antibody.
- a monoclonal antibody (S218-4) was raised against human chorionic gonadotrophin using the usual techniques. This was tested with catamers with the general formula:-
- the set of monomers used in the designated position D was extended to 'include both the L- and D- optical isomers of the common alpha amino acids, and the unusual amino acids, ⁇ -amino butyric acid, ⁇ -amino butyric acid, L-norcleucine, sarcosine, ornithine, L-norvaline, L-homophenylalanine, ⁇ -alanine.
- these sets of catamers were reacted with the monoclonal antibody it was found that the catamers which reacted strongly were:-
- This Example illustrates the application of the invention to the detection of a mimotope to a receptor which is not an antigen to which an antibody has been raised.
- This Example detects mimotopes of a receptor to which a virion binds.
- the test system for detecting binding to catamers has to be modified.
- the synthesized catamers are allowed to react with influenza virus particles (strain A-Shearwater/1/72) . After reaction the catamers are washed to remove unbound virus particles. The presence of bound virus particles was detected by reacting with a polyclonal antibody (S227-1) which had been raised against the hae aglutinin of influenza virus A/Shearwater/1/72. Antibodies which had reacted with the bound virus were detected in the usual way by ELISA.
- a set of catamers was synthesized with the general formula:- Y- j -D--D-. -Lk-(solid support] where the end group, Y.. -, is ⁇ -alanyl- ⁇ -alanine.
- the set of monomers which was used in the designated positions D. and D fatigue consisted of the D- and L- optical isomers of the common alpha amino acids.
- the catamers After removal of the bound virus from the catamers, the catamers were reacted with the polyclonal antibody S227-1 at the same concentration as that used to detect bound virus to ensure that the peaks found were due to binding of virus rather than binding of the polyclonal antibody.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Méthode permettant de détecter ou de déterminer la séquence de monomères qui est un équivalent topographique du liant qui est complémentaire à un récepteur particulier présentant un intérêt, ladite méthode comprenant les étapes suivantes: 1. synthétisation d'une pluralité de catamères, chacun desdits catamères faisant partie de la formule générale D2-D1, D1 représentant un monomère désigné sélectionné dans un premier groupe de monomères, et D2 représentant un monomère désigné sélectionné dans un second groupe de monomères qui peut être égal au premier groupe de monomères ou différent; ladite pluralité de catamères comprenant des catamères dans lesquels chaque monomère désigné varie systématiquement de manière à comprendre des éléments du groupe respectif de monomères; 2. mise en contact de chaque catamère avec le récepteur présentant un intêret; et 3. détection ou déterminatin de la présence ou de l'absence de liants entre chaque catamère et ledit récepteur. La méthode peut également se rapporter à la synthèse d'autres pluralités de catamères, comprenant des catamères contenant des molécules intermédiaires, de manière à former une séquence de monomères qui est le mimotope du liant.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT86902772T ATE78097T1 (de) | 1985-04-22 | 1986-04-22 | Verfahren zur bestimmung von mimitopen. |
DE8686902772T DE3685930T2 (de) | 1985-04-22 | 1986-04-22 | Verfahren zur bestimmung von mimitopen. |
DK624986A DK165197C (da) | 1985-04-22 | 1986-12-22 | Fremgangsmaade til bestemmelse af mimotoper |
NO865215A NO168793C (no) | 1985-04-22 | 1986-12-22 | Fremgangsmaate for paavisning eller bestemmelse av mimotoper |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPH024085 | 1985-04-22 | ||
AUPH0240/85 | 1985-04-22 | ||
AU56478/86A AU592560B2 (en) | 1985-04-22 | 1986-04-22 | Improved method for determining mimotopes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986006487A1 true WO1986006487A1 (fr) | 1986-11-06 |
Family
ID=25631326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1986/000110 WO1986006487A1 (fr) | 1985-04-22 | 1986-04-22 | Methode de determination de mimotopes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1986006487A1 (fr) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0314402A2 (fr) | 1987-10-26 | 1989-05-03 | Schering Biotech Corporation | Anticorps monoclonaux contre l'interleukine-4 humaine et hybridomes qui les produisent |
FR2631451A1 (fr) * | 1988-05-13 | 1989-11-17 | Inst Nat Sante Rech Med | Procede de caracterisation de l'epitope intervenant dans une reaction antigene anticorps, kit ou necessaire pour la mise en oeuvre du procede |
EP0390612A1 (fr) | 1989-03-31 | 1990-10-03 | Synbiotics Corporation | Production de médicament utilisant des anticorps à réactions non croisées |
WO1991006356A1 (fr) * | 1989-10-31 | 1991-05-16 | Terrapin Technologies, Inc. | Procede d'identification de ligands de liaison d'analytes |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5182366A (en) * | 1990-05-15 | 1993-01-26 | Huebner Verena D | Controlled synthesis of peptide mixtures using mixed resins |
WO1994002225A1 (fr) * | 1992-07-27 | 1994-02-03 | Terrapin Technologies, Inc. | Familles de sorbants |
US5300425A (en) * | 1987-10-13 | 1994-04-05 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
US5340474A (en) * | 1988-03-24 | 1994-08-23 | Terrapin Technologies, Inc. | Panels of analyte-binding ligands |
US5409611A (en) * | 1988-03-24 | 1995-04-25 | Terrapin Technoogies, Inc. | Method to identify analyte-binding ligands |
US5422426A (en) * | 1991-06-18 | 1995-06-06 | Eli Lilly And Company | Rapid synthesis and screening of peptide mimetics |
US5438119A (en) * | 1988-05-02 | 1995-08-01 | The Regents Of The University Of California | Method of obtaining a peptide with desired target property |
US5489678A (en) * | 1989-06-07 | 1996-02-06 | Affymax Technologies N.V. | Photolabile nucleoside and peptide protecting groups |
US5492807A (en) * | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5510240A (en) * | 1990-07-02 | 1996-04-23 | The Arizona Board Of Regents | Method of screening a peptide library |
EP0710724A2 (fr) | 1994-10-06 | 1996-05-08 | Akzo Nobel N.V. | Antigènes de Toxoplasma gondii |
WO1996024610A1 (fr) * | 1995-02-06 | 1996-08-15 | Chiron Mimotopes Pty. Ltd. | Banques combinatoires de tripeptides ramifies utiles pour traiter les troubles lies a l'activateur du plasminogene urokinase |
EP0773227A1 (fr) * | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Collections d'oligomères diverses, utiles pour préparer des médicaments, réactifs diagnostiques pesticides et herbicides |
EP0775746A2 (fr) | 1995-07-03 | 1997-05-28 | Akzo Nobel N.V. | Vaccin contre la coccidiose aviaire |
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5763570A (en) * | 1987-10-13 | 1998-06-09 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5840841A (en) * | 1990-05-15 | 1998-11-24 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
US5908919A (en) * | 1993-10-01 | 1999-06-01 | Terrapin Technologies | Urethane mediated, GST specific molecular release systems |
US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
US5958792A (en) * | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
US5994083A (en) * | 1993-05-11 | 1999-11-30 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable |
US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US6054438A (en) * | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
US6075121A (en) * | 1990-05-15 | 2000-06-13 | Chiron Corporation | Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such |
US6660276B1 (en) | 1994-02-16 | 2003-12-09 | The University Of Virginia Patent Foundation | Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor |
US6849462B1 (en) | 1991-11-22 | 2005-02-01 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US6919211B1 (en) | 1989-06-07 | 2005-07-19 | Affymetrix, Inc. | Polypeptide arrays |
US6955915B2 (en) | 1989-06-07 | 2005-10-18 | Affymetrix, Inc. | Apparatus comprising polymers |
US7056666B2 (en) | 1990-12-06 | 2006-06-06 | Affymetrix, Inc. | Analysis of surface immobilized polymers utilizing microfluorescence detection |
US7378236B1 (en) | 1994-06-17 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for analyzing gene expression patterns |
US7442499B2 (en) | 1994-06-17 | 2008-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Substrates comprising polynucleotide microarrays |
US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US7691330B1 (en) | 1991-11-22 | 2010-04-06 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US7811751B2 (en) | 1988-05-03 | 2010-10-12 | Oxford Gene Technology Limited | Analysing polynucleotide sequences |
US7888494B2 (en) | 1988-05-03 | 2011-02-15 | Oxford Gene Therapy Limited | Analysing polynucleotide sequences |
WO2012089748A1 (fr) | 2010-12-29 | 2012-07-05 | Intervet International B.V. | Antigène vaccinal contre la babésiose canine |
WO2012143488A1 (fr) | 2011-04-21 | 2012-10-26 | The University Court Of The University Of Aberdeen | Protéine destinée à être utilisée comme médicament |
WO2013034682A1 (fr) | 2011-09-08 | 2013-03-14 | Umc Utrecht Holding B.V. | Vaccin basé sur la protéine analogue à un superantigène staphylococcique 3 (ssl3) |
WO2013113865A1 (fr) | 2012-02-03 | 2013-08-08 | The Pirbright Institute | Vaccin à vecteur eimeria contre le campylobacter jejuni |
WO2014114812A1 (fr) | 2013-01-28 | 2014-07-31 | Danmarks Tekniske Universitet | Vaccin à sous-unité contre mycobacterium avium subsp. paratuberculosis à une ou plusieurs étapes |
US9366667B2 (en) | 2009-10-02 | 2016-06-14 | The Trustees Of Columbia University In The City Of New York | Piscine reovirus diagnostic compositions |
EP3085367A2 (fr) | 2007-03-20 | 2016-10-26 | Brandeis University | Compositions pour le diagnostic, le traitement et la prévention de la sclérose latérale amyotrophique et apparentées |
WO2021099444A1 (fr) | 2019-11-20 | 2021-05-27 | Intervet International B.V. | Nouveau vaccin contre heamophilus parasuis |
WO2021099446A1 (fr) | 2019-11-20 | 2021-05-27 | Intervet International B.V. | Nouveau vaccin contre heamophilus parasuis |
WO2021099458A1 (fr) | 2019-11-20 | 2021-05-27 | Intervet International B.V. | Nouveau vaccin contre haemophilus parasuis |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984002983A1 (fr) * | 1983-01-21 | 1984-08-02 | Frederick James Primus | Antigenes specifiques de la famille cea (antigene carcino-embryonaire), anticorps specifiques de ces antigenes et leurs procedes d'utilisation |
WO1984003564A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Procede de determination de sequences d'acides amines antigeniquement actives |
WO1984003506A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Sequences d'acides amines antigeniquement actives |
AU2542884A (en) * | 1983-03-08 | 1984-09-20 | Chiron Mimotopes Pty Ltd | Immunogenic deteminants of foot and mouth disease virus |
WO1985002121A1 (fr) * | 1983-11-07 | 1985-05-23 | The Wistar Institute | Reponse immune aux tumeurs et virus induits par des anticorps anti-idiotypes |
AU3656084A (en) * | 1983-12-12 | 1985-06-20 | Miles Laboratories Inc. | Nucleic acid hybridization assay employing antibodies to intercalation complexes |
AU3656384A (en) * | 1983-12-12 | 1985-06-20 | Miles Laboratories Inc. | Hybridization assay employing labeledprobe and anti-hybrid |
AU3656284A (en) * | 1983-12-12 | 1985-06-20 | Miles Laboratories Inc. | Hybridization assay with immobilization of hybrids by anti- hybrid binding |
AU4533985A (en) | 1984-07-24 | 1986-01-30 | Coselco Mimotopes Pty Ltd | Method for determining mimotopes |
-
1986
- 1986-04-22 WO PCT/AU1986/000110 patent/WO1986006487A1/fr active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984002983A1 (fr) * | 1983-01-21 | 1984-08-02 | Frederick James Primus | Antigenes specifiques de la famille cea (antigene carcino-embryonaire), anticorps specifiques de ces antigenes et leurs procedes d'utilisation |
WO1984003564A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Procede de determination de sequences d'acides amines antigeniquement actives |
WO1984003506A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Sequences d'acides amines antigeniquement actives |
AU2542884A (en) * | 1983-03-08 | 1984-09-20 | Chiron Mimotopes Pty Ltd | Immunogenic deteminants of foot and mouth disease virus |
WO1985002121A1 (fr) * | 1983-11-07 | 1985-05-23 | The Wistar Institute | Reponse immune aux tumeurs et virus induits par des anticorps anti-idiotypes |
AU3656084A (en) * | 1983-12-12 | 1985-06-20 | Miles Laboratories Inc. | Nucleic acid hybridization assay employing antibodies to intercalation complexes |
AU3656384A (en) * | 1983-12-12 | 1985-06-20 | Miles Laboratories Inc. | Hybridization assay employing labeledprobe and anti-hybrid |
AU3656284A (en) * | 1983-12-12 | 1985-06-20 | Miles Laboratories Inc. | Hybridization assay with immobilization of hybrids by anti- hybrid binding |
AU4533985A (en) | 1984-07-24 | 1986-01-30 | Coselco Mimotopes Pty Ltd | Method for determining mimotopes |
Non-Patent Citations (5)
Title |
---|
EMBO J., vol. 3, no. 6, 1984, pages 1295 - 1300 |
PNAS, vol. 82, 1985, pages 178 - 182 |
PNAS, vol. 87, 1984, pages 3998 - 4002 |
Scientific American, February 1983 pages 48-56 (page 50 lines 33-39), R.A. LERNER, "Synthetic Vaccines" * |
See also references of EP0220245A4 * |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605448B1 (en) | 1985-08-28 | 2003-08-12 | George Pieczenik | Method and means for sorting and identifying biological information |
US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
US6054438A (en) * | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
US5763570A (en) * | 1987-10-13 | 1998-06-09 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5541070A (en) * | 1987-10-13 | 1996-07-30 | Kauvar; Lawrence M. | Method to identify and characterize candidate drugs |
US5300425A (en) * | 1987-10-13 | 1994-04-05 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
EP0314402A2 (fr) | 1987-10-26 | 1989-05-03 | Schering Biotech Corporation | Anticorps monoclonaux contre l'interleukine-4 humaine et hybridomes qui les produisent |
US5133866A (en) * | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
US5340474A (en) * | 1988-03-24 | 1994-08-23 | Terrapin Technologies, Inc. | Panels of analyte-binding ligands |
US5409611A (en) * | 1988-03-24 | 1995-04-25 | Terrapin Technoogies, Inc. | Method to identify analyte-binding ligands |
US5567317A (en) * | 1988-03-24 | 1996-10-22 | Terrapin Technologies, Inc. | Method to identify analyte-binding ligands |
US5438119A (en) * | 1988-05-02 | 1995-08-01 | The Regents Of The University Of California | Method of obtaining a peptide with desired target property |
US5641862A (en) * | 1988-05-02 | 1997-06-24 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US7811751B2 (en) | 1988-05-03 | 2010-10-12 | Oxford Gene Technology Limited | Analysing polynucleotide sequences |
US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US7888494B2 (en) | 1988-05-03 | 2011-02-15 | Oxford Gene Therapy Limited | Analysing polynucleotide sequences |
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
FR2631451A1 (fr) * | 1988-05-13 | 1989-11-17 | Inst Nat Sante Rech Med | Procede de caracterisation de l'epitope intervenant dans une reaction antigene anticorps, kit ou necessaire pour la mise en oeuvre du procede |
EP0390612A1 (fr) | 1989-03-31 | 1990-10-03 | Synbiotics Corporation | Production de médicament utilisant des anticorps à réactions non croisées |
US5889165A (en) * | 1989-06-07 | 1999-03-30 | Affymetrix, Inc. | Photolabile nucleoside protecting groups |
US5744305A (en) * | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US6955915B2 (en) | 1989-06-07 | 2005-10-18 | Affymetrix, Inc. | Apparatus comprising polymers |
US7087732B2 (en) | 1989-06-07 | 2006-08-08 | Affymetrix, Inc. | Nucleotides and analogs having photoremovable protecting groups |
US6124102A (en) * | 1989-06-07 | 2000-09-26 | Affymetrix, Inc. | Methods for determining receptor-ligand binding using probe arrays |
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US6600031B1 (en) * | 1989-06-07 | 2003-07-29 | Affymetrix, Inc. | Methods of making nucleic acid or oligonucleotide arrays |
US6919211B1 (en) | 1989-06-07 | 2005-07-19 | Affymetrix, Inc. | Polypeptide arrays |
US5489678A (en) * | 1989-06-07 | 1996-02-06 | Affymax Technologies N.V. | Photolabile nucleoside and peptide protecting groups |
WO1991006356A1 (fr) * | 1989-10-31 | 1991-05-16 | Terrapin Technologies, Inc. | Procede d'identification de ligands de liaison d'analytes |
AU654940B2 (en) * | 1989-10-31 | 1994-12-01 | Telik, Inc. | Method to identify analyte-binding ligands |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5948635A (en) * | 1990-02-15 | 1999-09-07 | University Of North Carolina At Chapel Hill | Totally Synthetic Affinity Reagents |
US5844076A (en) * | 1990-02-15 | 1998-12-01 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5852167A (en) * | 1990-02-15 | 1998-12-22 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5625033A (en) * | 1990-02-15 | 1997-04-29 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US6075121A (en) * | 1990-05-15 | 2000-06-13 | Chiron Corporation | Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such |
US5182366A (en) * | 1990-05-15 | 1993-01-26 | Huebner Verena D | Controlled synthesis of peptide mixtures using mixed resins |
US5840841A (en) * | 1990-05-15 | 1998-11-24 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5858670A (en) * | 1990-07-02 | 1999-01-12 | The Arizona Board Of Regents | Bio-oligomer libraries and a method of use thereof |
US5510240A (en) * | 1990-07-02 | 1996-04-23 | The Arizona Board Of Regents | Method of screening a peptide library |
US7056666B2 (en) | 1990-12-06 | 2006-06-06 | Affymetrix, Inc. | Analysis of surface immobilized polymers utilizing microfluorescence detection |
US7329496B2 (en) | 1990-12-06 | 2008-02-12 | Affymetrix, Inc. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5422426A (en) * | 1991-06-18 | 1995-06-06 | Eli Lilly And Company | Rapid synthesis and screening of peptide mimetics |
EP0773227A1 (fr) * | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Collections d'oligomères diverses, utiles pour préparer des médicaments, réactifs diagnostiques pesticides et herbicides |
US6864101B1 (en) | 1991-11-22 | 2005-03-08 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US6849462B1 (en) | 1991-11-22 | 2005-02-01 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US7691330B1 (en) | 1991-11-22 | 2010-04-06 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US7736906B2 (en) | 1991-11-22 | 2010-06-15 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
US6013462A (en) * | 1992-04-03 | 2000-01-11 | Terrapin Technologies, Inc. | Glutathione analogs as reagents |
US5801225A (en) * | 1992-07-27 | 1998-09-01 | Terrapin Technologies, Inc. | Sorbent families |
WO1994002225A1 (fr) * | 1992-07-27 | 1994-02-03 | Terrapin Technologies, Inc. | Familles de sorbants |
US5599901A (en) * | 1992-07-27 | 1997-02-04 | Terrapin Technologies, Inc. | Sorbent families |
US5994083A (en) * | 1993-05-11 | 1999-11-30 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable |
US6541210B1 (en) | 1993-05-11 | 2003-04-01 | Istituto Di Recerche Di Biologia Moleculare P. Angeletti S.P.A. | Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable |
US5908919A (en) * | 1993-10-01 | 1999-06-01 | Terrapin Technologies | Urethane mediated, GST specific molecular release systems |
US5670312A (en) * | 1993-11-19 | 1997-09-23 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
US5492807A (en) * | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
US6660276B1 (en) | 1994-02-16 | 2003-12-09 | The University Of Virginia Patent Foundation | Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor |
US7378236B1 (en) | 1994-06-17 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for analyzing gene expression patterns |
US7442499B2 (en) | 1994-06-17 | 2008-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Substrates comprising polynucleotide microarrays |
US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
EP0710724A2 (fr) | 1994-10-06 | 1996-05-08 | Akzo Nobel N.V. | Antigènes de Toxoplasma gondii |
WO1996024610A1 (fr) * | 1995-02-06 | 1996-08-15 | Chiron Mimotopes Pty. Ltd. | Banques combinatoires de tripeptides ramifies utiles pour traiter les troubles lies a l'activateur du plasminogene urokinase |
US5627210A (en) * | 1995-02-06 | 1997-05-06 | Chiron Corporation | Branched combinatorial libraries |
US5958792A (en) * | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
EP0775746A2 (fr) | 1995-07-03 | 1997-05-28 | Akzo Nobel N.V. | Vaccin contre la coccidiose aviaire |
EP3085367A2 (fr) | 2007-03-20 | 2016-10-26 | Brandeis University | Compositions pour le diagnostic, le traitement et la prévention de la sclérose latérale amyotrophique et apparentées |
US9366667B2 (en) | 2009-10-02 | 2016-06-14 | The Trustees Of Columbia University In The City Of New York | Piscine reovirus diagnostic compositions |
US9395356B2 (en) | 2009-10-02 | 2016-07-19 | The National Veterinary Institute | Piscine reovirus immunogenic compositions |
WO2012089748A1 (fr) | 2010-12-29 | 2012-07-05 | Intervet International B.V. | Antigène vaccinal contre la babésiose canine |
WO2012143488A1 (fr) | 2011-04-21 | 2012-10-26 | The University Court Of The University Of Aberdeen | Protéine destinée à être utilisée comme médicament |
WO2013034682A1 (fr) | 2011-09-08 | 2013-03-14 | Umc Utrecht Holding B.V. | Vaccin basé sur la protéine analogue à un superantigène staphylococcique 3 (ssl3) |
WO2013113865A1 (fr) | 2012-02-03 | 2013-08-08 | The Pirbright Institute | Vaccin à vecteur eimeria contre le campylobacter jejuni |
WO2014114812A1 (fr) | 2013-01-28 | 2014-07-31 | Danmarks Tekniske Universitet | Vaccin à sous-unité contre mycobacterium avium subsp. paratuberculosis à une ou plusieurs étapes |
WO2021099444A1 (fr) | 2019-11-20 | 2021-05-27 | Intervet International B.V. | Nouveau vaccin contre heamophilus parasuis |
WO2021099446A1 (fr) | 2019-11-20 | 2021-05-27 | Intervet International B.V. | Nouveau vaccin contre heamophilus parasuis |
WO2021099458A1 (fr) | 2019-11-20 | 2021-05-27 | Intervet International B.V. | Nouveau vaccin contre haemophilus parasuis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4833092A (en) | Method for determining mimotopes | |
WO1986006487A1 (fr) | Methode de determination de mimotopes | |
US5194392A (en) | Method of determining mimotopes | |
US5541070A (en) | Method to identify and characterize candidate drugs | |
EP0818467B1 (fr) | Réseau peptidique aligné et procédé rapide et rationnel de dépistage d'une liaison ou d'un site d'interaction d'une protéine en utilisant celui-ci | |
Dambinova et al. | The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy | |
JP5611831B2 (ja) | リウマチ性関節炎自己抗体との免疫反応性合成ペプチド | |
Sioud et al. | Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto) antigens that may trigger B and T cell responses in autoimmune diseases | |
US5955582A (en) | Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay | |
Atanassov et al. | New Zealand white rabbits immunized with RNA‐complexed total histones develop an autoimmune‐like response | |
Fiordalisi et al. | Site-Directed Mutagenesis of. kappa.-Bungarotoxin: Implications for Neuronal Receptor Specificity | |
IE881289L (en) | A method for the selective immunological determination of¹intact procollagen peptide (Type III) and procollagen (Type¹III) in body fluids, and means for carrying it out | |
Van Regenmortel | Structure of antigens | |
AU592560B2 (en) | Improved method for determining mimotopes | |
EP0351410A1 (fr) | Peptide de liaison de complement | |
Ruben et al. | Antibodies to calmodulin during experimental Trypanosoma brucei rhodesiense infections in rabbits | |
Herfurth et al. | Determination of peptide regions exposed at the surface of the bacterial ribosome with antibodies against synthetic peptides | |
Zegers et al. | Immunological recognition of peptides in medicine and biology | |
JP4387945B2 (ja) | 抗イディオタイプ抗体、該抗イディオタイプ抗体の作成方法、及び該抗イディオタイプ抗体を用いたイディオタイプ抗体の調製方法 | |
JPH06293798A (ja) | ヒトパルボウイルスb19のエピトープ関連ペプチド | |
US6800462B2 (en) | Production of recombinant proteins in vivo and use for generating antibodies | |
WO1996006357A1 (fr) | Criblage pour des composes a potentiel therapeutique | |
DE19534988A1 (de) | Verfahren zur Herstellung und Anwendung synthetischer, biotinylierter Peptide | |
JPH05339295A (ja) | 抗体の作成方法 | |
JPH05308992A (ja) | モノクローナル抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): DK JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1986902772 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1986902772 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1986902772 Country of ref document: EP |